Hologic’s Tim Simpson Discusses the Future of Cervical Cancer Screening.
We just had a string of successful biotech IPOs. Now what?
When CG Oncology’s $CGON IPO hit a few weeks ago, its success with investors startled a wide swathe of biotech watchers who had grown accustomed